01
HBOT
Hyperbaric oxygen therapy, when clinically indicated.
Private, individualized recovery
POUYAN METHOD™
We are not part of the old healthcare system. We are creating what comes next. Welcome to the future of healing.
A cutting-edge, multifaceted healing system designed around the whole person. Advanced technologies and therapeutic strategies converge with a carefully sequenced psycho-spiritual approach to psychedelic and sacred medicine, supported by holistic care, conscious wellness, superfood nutrition, preparation, and integration.
Founder statement · 01
What I Built Was the Opposite of Rehab.
I went through 17 rehabs. I know what it feels like to become a number inside a model that has already decided what your recovery should look like.
So I built the opposite: a private environment, no group therapy by default, no one-size-fits-all package, no industrial cafeteria food. Every decision begins with the person in front of us.
This is not a menu of treatments. It is an individualized sequence of preparation, care, recovery, and integration.
The integrated system · 02
Pouyan
Method™
An adaptive sequence rather than a standardized package. Assessment determines what comes next—and what does not.
Not every guest receives every therapy. Medical screening, suitability, consent, and ongoing response guide the plan.
Individual
Guest
01Assessment
02Preparation
03Individualized Therapies
04Psychedelic / Plant-Medicine Work When Appropriate
05Recovery
06Integration
Medical feature · 03
Brain Repair IV Drip Protocol
A named IV protocol formulated and administered by the medical team as one possible part of individualized care.
The founder’s clinical rationale is that nutritional and physiologic support may help create a more stable foundation while a guest moves through demanding recovery work. The formulation, timing, and suitability are determined medically—not from a fixed recipe.
In the founder’s experience, some guests report meaningful changes during integrated care. Those observations inform the protocol, but they are not proof that an IV rebuilds the brain, resets receptors, reverses medication-related injury, or reliably accelerates tapering.
Those mechanisms and outcomes remain hypotheses requiring appropriate clinical research. Medication changes, including benzodiazepine or SSRI tapering, require individualized medical management.
Medical screening
Individual formulation
Monitored administration
Integrated follow-through
The protocol · 04
One system.
Many instruments.
Modalities are not a checklist. They are considered, sequenced, modified, or excluded according to screening, objectives, response, and medical judgment.
02
NAD+ IV
Physician-directed infusion within an individualized plan.
03
Ibogaine
Considered only after rigorous screening and risk review.
04
Ayahuasca
Facilitated ceremonial work when appropriate and lawful.
05
DMT / Changa
A carefully screened, context-dependent modality.
06
Psilocybin
Preparation, supported experience, and integration.
07
5-MeO-DMT
Never routine; suitability is individually determined.
08
Red Light
Photobiomodulation as a noninvasive supportive therapy.
09
Infrared Sauna
Heat-based recovery support with clinical oversight.
10
Bodywork
Massage designed around the guest’s physical state.
11
Yoga & Breathwork
Nervous-system-aware movement and breath practice.
12
Nutrition
Whole-food nourishment built around individual needs.
13
Private Rooms
A private room and bathroom—not institutional living.
14
Organic Environment
Considered materials, linens, toiletries, and food.
What the science says—and what it does not say
Credibility begins with the boundary.
01
Evidence
Published research can inform risk, dosing context, and what has been observed in defined populations. Its strength varies sharply by intervention and outcome.
02
Clinical experience
Fifteen years of hands-on observation can guide questions and individualized decisions. It is valuable—but it is not the same as controlled evidence.
03
Hypothesis
Proposed mechanisms may offer a rationale for further study. They should never be presented as proven human outcomes.
Selected evidence · 05
THE RESEARCH
LIBRARY
A curated reading room—not a claim of proof. Each card pairs the measured finding with the limitation that should travel with it.
HBOT · FDA sourceHyperbaric Oxygen Therapy: Get the Facts
Regulatory consumer guidance · 13 FDA-cleared indications
Hyperbaric Oxygen Therapy: Get the Facts
Regulatory consumer guidance · 13 FDA-cleared indications
Finding
The FDA describes the specific conditions for which hyperbaric chambers have been cleared for marketing.
Limitation
Clearance for listed indications does not establish efficacy for addiction, psychiatric conditions, or unlisted uses.
HBOT · 2026HBOT for traumatic brain injury outcomes
Systematic review and meta-analysis · 8 studies · 570 TBI participants
HBOT for traumatic brain injury outcomes
Systematic review and meta-analysis · 8 studies · 570 TBI participants
Finding
The analysis reported domain-specific signals in cognition and sleep outcomes.
Limitation
PTSD and emotional outcomes remained uncertain, and study differences limit broad conclusions.
HBOT · 2022HBOT for persistent post-concussion symptoms
Systematic review · Clinical studies in mild TBI / PPCS
HBOT for persistent post-concussion symptoms
Systematic review · Clinical studies in mild TBI / PPCS
Finding
The review identified possible benefits across selected outcomes in some studies.
Limitation
Evidence was limited and heterogeneous, with protocols and comparison conditions varying substantially.
HBOT · 2016HBOT for mild traumatic brain injury and PTSD
Rapid evidence assessment · 12 randomized trials
HBOT for mild traumatic brain injury and PTSD
Rapid evidence assessment · 12 randomized trials
Finding
The assessment found mixed results across trials and outcomes.
Limitation
Methodologic variation and sham-comparator questions prevented a definitive conclusion.
AYAHUASCA · 2018Rapid antidepressant effects of ayahuasca
Randomized, double-blind, placebo-controlled trial · 29 patients with treatment-resistant depression
Rapid antidepressant effects of ayahuasca
Randomized, double-blind, placebo-controlled trial · 29 patients with treatment-resistant depression
Finding
A single session produced greater short-term improvement in depression scores than placebo at selected time points.
Limitation
The trial was small and short-term; findings do not establish durable benefit or broad suitability.
AYAHUASCA · 2026Long-term psychological outcomes after ayahuasca
Systematic review · 18 prospective studies
Long-term psychological outcomes after ayahuasca
Systematic review · 18 prospective studies
Finding
Prospective studies suggested preliminary longer-term changes in selected psychological measures.
Limitation
The literature needs larger controlled studies and more consistent methods before causal claims can be made.
AYAHUASCA · 2022Ayahuasca and depression
Scientific review · Human clinical literature
Ayahuasca and depression
Scientific review · Human clinical literature
Finding
The review discussed emerging evidence for antidepressant effects and possible mechanisms.
Limitation
The evidence base remained early, with small samples and limited controlled follow-up.
AYAHUASCA · 2022Classic psychedelics for depressive symptoms
Systematic review and meta-analysis · Studies including ayahuasca and other classic psychedelics
Classic psychedelics for depressive symptoms
Systematic review and meta-analysis · Studies including ayahuasca and other classic psychedelics
Finding
Pooled results suggested reductions in depressive symptoms across the included psychedelic literature.
Limitation
Substances, settings, designs, and follow-up periods differed; pooled findings are not specific proof for one protocol.
IBOGAINE · 2018Ibogaine detoxification in opioid use disorder
Observational study · 50 participants with OUD
Ibogaine detoxification in opioid use disorder
Observational study · 50 participants with OUD
Finding
Participants showed changes in withdrawal and craving measures after treatment.
Limitation
Without randomization or a control group, the study cannot establish that ibogaine caused the observed changes.
IBOGAINE · 2021Safety of ibogaine administration
Open-label observational safety study · 14 patients with OUD
Safety of ibogaine administration
Open-label observational safety study · 14 patients with OUD
Finding
The study documented clinically relevant, reversible QTc prolongation and ataxia.
Limitation
The small sample does not define population-level risk; findings underscore the need for intensive screening and monitoring.
IBOGAINE · 2019Ibogaine and neurotrophic factor expression
Preclinical study · Animal / laboratory models
Ibogaine and neurotrophic factor expression
Preclinical study · Animal / laboratory models
Finding
The study examined changes involving GDNF and BDNF expression after ibogaine exposure.
Limitation
Preclinical molecular findings cannot be translated directly into treatment outcomes in humans.
IBOGAINE · 2019Neurotrophic mechanisms and ibogaine
Mechanistic review · Preclinical and mechanistic literature
Neurotrophic mechanisms and ibogaine
Mechanistic review · Preclinical and mechanistic literature
Finding
The review discusses GDNF-related and other proposed neurobiological pathways associated with ibogaine.
Limitation
Mechanistic hypotheses are not clinical proof of safety, efficacy, or brain repair in people.
IBOGAINE · 2018Long-term outcomes following ibogaine treatment
Observational follow-up · Participants followed for 12 months
Long-term outcomes following ibogaine treatment
Observational follow-up · Participants followed for 12 months
Finding
The study reported changes in opioid use and related outcomes over follow-up among respondents.
Limitation
Attrition, self-report, selection effects, and the absence of a randomized control limit causal interpretation.
Research evolves. Linked records should be reviewed in full with qualified clinicians, including methods, adverse events, contraindications, and applicability to the individual.
Time as a therapeutic resource · 06
Why four weeks—or longer.
Depth takes time. Four weeks is not a universal medical requirement; it is often the beginning of enough space to prepare carefully and recover without rushing.
01
Preparation
History, goals, medication review, diagnostics, and trust.
02
Medical screening
Suitability and risk are assessed before intensive interventions.
03
Recovery
The body and nervous system are given protected time after demanding work.
04
Integration
Insights become choices, routines, relationships, and a plan for what follows.
Program length is individualized. Depending on needs, response, and clinical judgment, care may extend for weeks or months.
The environment · 07
Nothing around you should work against your recovery.
Food and environment are not background details. They are the conditions in which the work happens.
Organic whole foods
Soy-free
Gluten-free
Dairy & casein-free
No seed oils
No highly processed foods
Superfood juices
Organic linens & toiletries
Private rooms & bathrooms
My Why · 08
I could not accept that the existing model was the only model.
I speak from my own history: 17 rehabs, the disorientation of being treated like a diagnosis, and the loss of my brother to suicide. That loss is part of why I refused to stop asking whether care could be more personal, more rigorous, and more human.
I did not build Holistic Sanctuary because I believe one intervention saves everyone. I built it because people deserve to be seen clearly—and because preparation, medical responsibility, environment, and integration should not be separated from the work.
My promise is not an outcome. It is that we will take the individual seriously.
Fifteen years of hands-on experience
A private conversation
You don’t need another program. You may need a different approach.
Begin with a confidential assessment of your history, circumstances, and what responsible next steps could look like.